- Home
- Clinical Trials
Coeliac Disease Study Dunedin 101
Coeliac Disease Study
Dunedin
Help support research aimed at advancing treatments for yourself and others living with coeliac disease
Please note that this study has now closed. However, we encourage you to pre-register your interest for future coeliac disease studies here.
Description
What to expect
Study details
Ages
18 - 75 years old
Duration
Up to 31 weeks
Compensation
Participants will be reimbursed for study visits and reasonable study-related travel expenses
Eligibility Criteria
You may be eligible to take part if you:
- Adults aged 18 - 75 years
- Have well-controlled Coeliac disease confirmed by a biopsy
- Have been following a gluten free diet as best as you can for at least six months
- Test positive for specific genetic markers (HLA-DQ2 and/or HLA-DQ8) during the screen tests.
You will be excluded from the study if you:
- Have other inflammatory gastrointestinal or systemic autoimmune diseases (e.g., Inflammatory Bowel Disease, Colitis)
- Are currently using or have used systemic immunosuppressants or corticosteroids, such as predsnisone, in the past 12 weeks
Other exclusion criteria may apply
Locations
Description
Coeliac disease is an autoimmune disorder triggered by eating gluten, found in wheat, rye, and barley, in genetically predisposed individuals. When gluten is not fully digested, it triggers an immune response that leads to damage in the intestine and can result in symptoms and complications like nutritional deficiencies, skin rashes, and a higher risk of other autoimmune diseases.
The only current treatment is a strict, lifelong gluten-free diet, which is very challenging and can still result in accidental gluten consumption and ongoing symptoms.
What to expect
Momentum is running a clinical research study testing a new investigational treatment that aims to prevent immune cells from reacting to gluten in people with Coeliac Disease.
The study involves three doses which consist of at least one dose of the study medication and a placebo and several gluten challenges.
The study lasts up to 31 weeks with 6 weeks of initial screening, followed by the study treatment on 3 occasions over 24 weeks, and 1 month of follow-up after the treatment ends.
This study is now closed
Please note that this study has now closed. However, we encourage you to pre-register your interest for future coeliac disease studies here.